Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing

Clinical Therapeutics

Volumn 24, Issue 7, 2002, Pages 1090-1104

  Burgess, David S ^a,b   Waldrep, Travis ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Continuous infusion; Pharmacodynamics; Pharmacokinetics; Piperacillin tazobactam

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; DRUG DERIVATIVE; PENICILLANIC ACID; PENICILLIN DERIVATIVE; PIPERACILLIN; TAZOBACTAM;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; HUMAN EXPERIMENT; KLEBSIELLA PNEUMONIAE; MALE; NONHUMAN; NORMAL HUMAN; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION;

ADULT; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; PSEUDOMONAS AERUGINOSA;

EID: 0036022893     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80021-2     Document Type: Article

References (42)

1. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
2. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
3. Killing and regrowth of bacteria in vitro: A review
4. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
5. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents
6. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models
7. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
8. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients
9. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia
10. Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia
11. Intermittent and continuous ceftazidime infusion in critically ill trauma patients
12. Cefuroxime by continuous infusion: A new standard of care?
13. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections
14. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion versus intermittent bolus injection in septicaemic melioidosis
15. Prediction of creatinine clearance from serum creatinine
16. Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography
17. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
18. Continuous infusion of beta-lactam antibiotics
19. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats
20. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats
21. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion
22. Continuous infusion ceftazidime in intensive care: A randomized controlled trial
23. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime
24. Serum bactericidal activity of ceftazidime: Continuous infusion versus intermittent injections
25. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis
26. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: Clinical outcome, microbiology and pharmacokinetics
27. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia
28. Low-dose continuous infusion ceftazidime monotherapy in low-risk febrile neutropenic patients
29. Continuous ceftazidime infusions in critically ill surgical patients
30. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion
31. Pharmacokinetic and economic evaluation of piperacillin/tazobactam administered either continuous or intermittent infusion with once-daily gentamicin
32. Pharmacokinetics and pharmacoeconomic evaluation of ticarcillin-clavulanate administered as either continuous or intermittent infusion with once-daily gentamicin
33. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion
34. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin/tazobactam program in a large community teaching hospital
35. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia
36. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill
37. In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates
38. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients
39. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin
40. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae